Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells $40,619.60 in Stock

Posted by on May 23rd, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) CFO Kyle Piskel sold 3,115 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $13.04, for a total transaction of $40,619.60. Following the completion of the sale, the chief financial officer owned 256,725 shares in the company, valued at $3,347,694. This represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kyle Piskel also recently made the following trade(s):

  • On Wednesday, March 11th, Kyle Piskel sold 18,672 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.17, for a total transaction of $245,910.24.

Adaptive Biotechnologies Price Performance

NASDAQ ADPT opened at $13.88 on Friday. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -42.06 and a beta of 2.16. The company’s fifty day moving average is $13.79 and its two-hundred day moving average is $15.62. Adaptive Biotechnologies Corporation has a 52-week low of $8.50 and a 52-week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The company had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period last year, the business posted ($0.20) EPS. As a group, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Allianz Asset Management GmbH lifted its holdings in Adaptive Biotechnologies by 305.8% during the 3rd quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after purchasing an additional 242,474 shares during the last quarter. Lisanti Capital Growth LLC bought a new position in Adaptive Biotechnologies during the 3rd quarter valued at about $4,476,000. Affinity Wealth Management LLC bought a new position in Adaptive Biotechnologies during the 3rd quarter valued at about $4,541,000. UBS Group AG lifted its holdings in Adaptive Biotechnologies by 101.6% during the 4th quarter. UBS Group AG now owns 511,927 shares of the company’s stock valued at $8,314,000 after purchasing an additional 257,947 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB bought a new position in Adaptive Biotechnologies during the 3rd quarter valued at about $7,405,000. 99.17% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ADPT. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. JPMorgan Chase & Co. decreased their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. BTIG Research restated a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Finally, Guggenheim reaffirmed a “buy” rating and set a $21.00 price objective on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.57.

Check Out Our Latest Research Report on ADPT

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

Featured Articles

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.